Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005263 | 0.86 | CNR2 (0.58) | RAB9APOLBSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL14029902 | 0.86 | CNR2 (0.52) | KMT2ALMNAGAACNR2 | |
| SCHEMBL14030758 | 0.78 | PADI2 (0.45) | MAPTLMNAALDH1A1HTT | |
| SCHEMBL14005267 | 0.76 | MAPT (0.54) | RAB9APOLBKMT2AKDM4EMAPT | |
| SCHEMBL14030749 | 0.74 | ACACB (0.43) | SMN1; SMN2KDM4EHSD17B10TSHRMAPT | |
| SCHEMBL14030760 | 0.71 | KMT2A (0.46) | RAB9AKMT2AMAPTGAAALDH1A1 | |
| SCHEMBL14005266 | 0.71 | RAB9A (0.55) | RAB9AKMT2AKDM4EMAPK10MAPT | |
| SCHEMBL4745657 | 0.71 | CNR2 (0.76) | LMNACNR2 | |
| SCHEMBL14025800 | 0.70 | MAPT (0.66) | RAB9APOLBSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL7080320 | 0.70 | MAPT (0.73) | RAB9APOLBSMN1; SMN2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | RAB9A 1363/4885POLB 2589/4885SMN1; SMN2 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.